PMID- 29261005
OWN - NLM
STAT- MEDLINE
DCOM- 20190403
LR  - 20240327
IS  - 1555-8576 (Electronic)
IS  - 1538-4047 (Print)
IS  - 1538-4047 (Linking)
VI  - 19
IP  - 3
DP  - 2018 Mar 4
TI  - Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue 
      sarcoma: An observational study.
PG  - 198-204
LID - 10.1080/15384047.2017.1416275 [doi]
AB  - Sarcomas are rare but malignant tumors with high risks of local recurrence and 
      distant metastasis. Anti-angiogenic therapy is a potential strategy against 
      un-controlled and not-organized tumor angiogenesis. We aimed to assess the safety 
      and efficacy of apatinib, an oral tyrosine kinase inhibitor targeting vascular 
      endothelial growth factor receptor-2, in patients with advanced sarcoma. 
      Thirty-one patients who received initial apatinib between September 2015 and 
      August 2016 were retrospectively reviewed. Among them, 19 (61.3%) patients were 
      heavily pretreated with two or more lines of cytotoxic chemotherapy. Apatinib was 
      given at a start-dose of 425 mg qd. During therapy, 9 (29.0%) patients required 
      dose interruption and 7 (22.6%) needed dose reduction, and the mean dosage of 
      apatinib was 372.9 +/- 68.4 mg/day. In the study cohort, one patient was treated as 
      adjunctive therapy and 6 patients stopped treatment before radiographic response 
      assessment. Thus, 24 patients were eligible for tumor response evaluation. The 
      objective response rate was 33.3% and clinical benefit rate was as high as 75.0%. 
      The progression free survival was 4.25 (95% confidence interval [CI], 2.22-5.11) 
      months, whereas the overall survival was 9.43 (95% CI, 6.64-18.72) months. 
      Compared with other histological subtypes, leiomyosarcoma did not show 
      significant survival benefits. Most of the adverse events (AEs) were at grade 1 
      or 2. The main grade 3 AEs were hypertension (6.5%), hand foot skin reaction 
      (6.5%), and diarrhea (3.2%). In conclusion, apatinib showed promising efficacy 
      and acceptable safety profile in metastatic or recurrent sarcoma, giving 
      rationale clinical evidence to conduct clinical trials.
FAU - Zhu, Baorang
AU  - Zhu B
AD  - a Department of Oncology Minimally Invasive , The 307th Hospital of PLA, 
      Affiliated Hospital of Military Medical Sciences , Beijing , China.
FAU - Li, Jing
AU  - Li J
AD  - a Department of Oncology Minimally Invasive , The 307th Hospital of PLA, 
      Affiliated Hospital of Military Medical Sciences , Beijing , China.
FAU - Xie, Qiaosheng
AU  - Xie Q
AD  - a Department of Oncology Minimally Invasive , The 307th Hospital of PLA, 
      Affiliated Hospital of Military Medical Sciences , Beijing , China.
FAU - Diao, Liyan
AU  - Diao L
AD  - a Department of Oncology Minimally Invasive , The 307th Hospital of PLA, 
      Affiliated Hospital of Military Medical Sciences , Beijing , China.
FAU - Gai, Lvhua
AU  - Gai L
AD  - a Department of Oncology Minimally Invasive , The 307th Hospital of PLA, 
      Affiliated Hospital of Military Medical Sciences , Beijing , China.
FAU - Yang, Wuwei
AU  - Yang W
AD  - a Department of Oncology Minimally Invasive , The 307th Hospital of PLA, 
      Affiliated Hospital of Military Medical Sciences , Beijing , China.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20180124
PL  - United States
TA  - Cancer Biol Ther
JT  - Cancer biology & therapy
JID - 101137842
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Pyridines)
RN  - 5S371K6132 (apatinib)
RN  - EC 2.7.10.1 (KDR protein, human)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Bone Neoplasms/diagnostic imaging/*drug therapy/mortality/pathology
MH  - Child
MH  - Child, Preschool
MH  - Diarrhea/chemically induced/epidemiology
MH  - Female
MH  - Hand-Foot Syndrome/epidemiology/etiology
MH  - Humans
MH  - Hypertension/chemically induced/epidemiology
MH  - Kaplan-Meier Estimate
MH  - Leiomyosarcoma/diagnostic imaging/*drug therapy/mortality/pathology
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*drug therapy/mortality/pathology
MH  - Osteosarcoma/*drug therapy/mortality/pathology
MH  - Progression-Free Survival
MH  - Pyridines/pharmacology/*therapeutic use
MH  - Response Evaluation Criteria in Solid Tumors
MH  - Retrospective Studies
MH  - Tomography, X-Ray Computed
MH  - Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors
MH  - Young Adult
PMC - PMC5790336
OTO - NOTNLM
OT  - Soft tissue sarcoma
OT  - apatinib
OT  - efficacy
OT  - observational study
OT  - osteosarcoma
OT  - safety
OT  - targeted therapy
EDAT- 2017/12/21 06:00
MHDA- 2019/04/04 06:00
PMCR- 2019/01/24
CRDT- 2017/12/21 06:00
PHST- 2017/12/21 06:00 [pubmed]
PHST- 2019/04/04 06:00 [medline]
PHST- 2017/12/21 06:00 [entrez]
PHST- 2019/01/24 00:00 [pmc-release]
AID - 1416275 [pii]
AID - 10.1080/15384047.2017.1416275 [doi]
PST - ppublish
SO  - Cancer Biol Ther. 2018 Mar 4;19(3):198-204. doi: 10.1080/15384047.2017.1416275. 
      Epub 2018 Jan 24.